UK
Health analytics
Our health and the challenges healthcare systems face are changing. Patients have increasingly complex health needs due to multimorbidity, and they experience large inequalities in healthcare outcomes. Meanwhile, the assessment of medicines and corresponding payment mechanisms do not reflect the true value that good health brings to healthcare systems and society at large.
With our innovative and market-leading analytics, we aim to enable the transition of health systems globally from importers of illness to exporters of health by interpreting value between patients, manufacturers of medicines, payers, and other key stakeholders.
Why have we launched US access solutions?
Explore why LCP Health Analytics launched US Access Solutions, bringing integrated global expertise to pricing, access, and value consulting.
Shifting health systems from importers of illness to exporters of health
Combining strategic vision with innovative analytics
Our global team partners with clients in the life sciences and healthcare industries, bringing together strategic vision and market-leading analytics to drive three critical shifts:
- Moving from a single-disease focus to a holistic view of healthcare needs by uncovering increasingly complex, multimorbid, unmet patient needs, guiding targeted action, and advancing health equity.
- A broader view of the value of medicines and health: realigning how Health Technology Assessment organizations and payers value medicines, and the value of health to patients, populations, and economies.
- Improving health equity by embedding consideration of inequalities across the medicine life cycle.
Delivering integrated insights that drive maximum value
We bring together expertise across our service areas to deliver integrated insights that create the greatest value for our clients. We support organizations throughout the entire innovation lifecycle by:
-
Transforming real-world healthcare data into actionable insights that guide evidence-based decisions for providers, payers, patients, and policymakers from national institutions like the National Institutes of Health (NIH) and Centers for Medicare & Medicaid Services (CMS) to local care teams.
-
Applying scientific rigor to evaluate the economic and clinical value of healthcare interventions, enabling faster and broader patient access.
-
Developing holistic strategies for global market access and real-world evidence to drive commercial success.
-
Accelerating US access with value-based, evidence-driven solutions built on deep clinical insight and strategic consulting.
-
Creating integrated, compelling visual analytics, powered by AI to support engagement with medical, scientific, and policy leaders.
-
Leveraging large-scale human omics data and advanced analytics to increase the speed and cost-efficiency of drug development.
At LCP, we’re more than a service provider - we’re your strategic thought partner
We partner with clients from proposal to delivery, with senior experts providing hands-on project leadership across service areas. Our leadership experience in science, medicine, consulting, pharmaceuticals, and policy combined with strong partnerships with key decision-makers and state-of-the-art technology, methods, and expertise enables us to deliver insights that address the challenges of tomorrow.
Contact us to learn how we can bring clarity and insight in today’s increasingly complex life sciences and healthcare environment.
Until now there has been limited research on the impact of multi and comorbidities across different patient groups and how this progresses during the course of the disease. This study has highlighted the large variations in clinical need within the patient group.
Programme director, Data and Real World Evidence National Institute for Health and Care Excellence (NICE), UK organization providing guidance and advice to improve health and social care
Explore our focus areas
Medicines Nexus™
Prescription analytics platform
Our innovative prescription analytics platform delivering cutting-edge insights into the medicines market.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
Featured press
“Turning purpose into action” - LCP releases 2025 Impact Report
LCP has released its 2025 Impact Report, highlighting the actions the firm has taken across the year to play its part in building a healthier, fairer, and more resilient society.
LCP reports another year of sustainable growth driven by people, culture, and technology
LCP has announced a record income of £232 million (approx. $314 million) for the financial year 2024/25, representing a 10% increase on the previous year.
LCP Health Analytics partners with COTA to advance the use of US RWD to support HTA decision making internationally
LCP Health Analytics is partnering with COTA to explore how US real-world data (RWD) can support health technology assessments (HTA) in the United Kingdom (UK) and European Union (EU).
LCP Health Analytics launches US Access Solutions with two strategic hires
LCP’s Health Analytics practice has launched US Access Solutions, led by industry experts Kevin Patterson and Lee Ann Steadman, to support clients and drive growth in the market.
Get in touch
Contact us to learn more about how we can provide clarity and insight in today’s increasingly complex life sciences and healthcare environment.
